PortfoliosLab logoPortfoliosLab logo
ISIN
IE00B56GVS15
CUSIP
00B56GVS1
IPO Date
Jul 16, 1991

Highlights

Market Cap
$7.99B
Enterprise Value
$8.97B
EPS (TTM)
$0.91
PE Ratio
52.86
PEG Ratio
0.21
Total Revenue (TTM)
$1.56B
Gross Profit (TTM)
$1.02B
EBITDA (TTM)
$249.70M
Year Range
$25.17 - $48.32
Target Price
$44.00
ROA (TTM)
3.59%
ROE (TTM)
8.72%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

ALKS Performance Chart

Alkermes plc (ALKS) is up 71.8% since the beginning of the year. At $48 per share, ALKS is trading just below its 52-week high of $48. Investors who bought $1,000 worth of ALKS shares 5 years ago would now be looking at an investment worth $1,960.


Loading charts...

S&P 500 Index

Returns By Period

Alkermes plc (ALKS) has returned 71.80% so far this year and 64.29% over the past 12 months. Over the last ten years, ALKS has returned 1.29% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.


Alkermes plc

1D
4.45%
1M
30.62%
YTD
71.80%
6M
68.73%
1Y
64.29%
3Y*
12.97%
5Y*
14.41%
10Y*
1.29%

Benchmark (S&P 500 Index)

1D
-1.44%
1M
-1.45%
YTD
7.60%
6M
6.59%
1Y
22.24%
3Y*
19.20%
5Y*
11.54%
10Y*
13.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALKS Monthly Returns History

Based on dividend-adjusted daily data since Jul 16, 1991, ALKS's average daily return is +0.10%, while the average monthly return is +2.34%. At this rate, an investment would double in approximately 2.5 years.

Historically, 52% of months were positive and 48% were negative. The best month was Feb 2000 with a return of +189.4%, while the worst month was Jul 2002 at -71.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ALKS closed higher 47% of trading days. The best single day was Jul 27, 1995 with a return of +34.1%, while the worst single day was Jul 1, 2002 at -67.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202621.12%-11.18%17.48%-4.67%25.16%13.94%71.80%
20259.63%8.88%-3.82%-12.87%6.40%-6.53%-7.41%9.36%3.56%2.33%-3.65%-5.41%-2.71%
2024-2.49%9.76%-8.82%-9.35%-4.65%2.99%13.36%4.14%-1.62%-8.18%12.92%-0.90%3.68%
20239.61%-6.63%5.42%1.28%1.33%8.19%-6.45%-0.31%-4.04%-13.64%-0.21%14.91%6.16%
20229.63%-2.51%5.83%9.65%3.47%-0.20%-14.07%-7.54%-5.66%1.66%9.16%5.45%12.34%
20215.21%-9.29%-1.89%17.80%3.02%8.16%5.51%20.83%-1.34%-1.78%-27.63%6.11%16.59%

Benchmark Metrics

Alkermes plc has an annualized alpha of 15.66%, beta of 1.16, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since July 16, 1991.

  • This stock participated in 132.42% of S&P 500 Index downside but only 126.17% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
15.66%
Beta
1.16
0.11
Upside Capture
126.17%
Downside Capture
132.42%

Return for Risk

Risk / Return Rank

ALKS ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


ALKS Risk / Return Rank: 8282
Overall Rank
ALKS Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
ALKS Sortino Ratio Rank: 8181
Sortino Ratio Rank
ALKS Omega Ratio Rank: 8080
Omega Ratio Rank
ALKS Calmar Ratio Rank: 8383
Calmar Ratio Rank
ALKS Martin Ratio Rank: 8282
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Alkermes plc (ALKS) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ALKSBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-0.20

Sortino ratioReturn per unit of downside risk

-0.11

Omega ratioGain probability vs. loss probability

1.29

1.32

-0.03

Calmar ratioReturn relative to maximum drawdown

2.91

2.46

+0.45

Martin ratioReturn relative to average drawdown

6.76

10.92

-4.16

Dividends

Dividend History


Alkermes plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Alkermes plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alkermes plc was 96.14%, occurring on Jul 11, 2002. The portfolio has not yet recovered.

The current Alkermes plc drawdown is 50.97%.


Related event

Drawdown

Fall

Recovery

Underwater

Dot-com crash2000–2002
-96.14%Jul 2002
2y 4mo
26y 4moMar 2000 - now
1995 bear market1995
-92.95%Jan 1995
2y 12mo2y 1mo
5y 1moJan 1992 - Feb 1997
1997 bear market1997
-64.67%Apr 1997
2mo 8d1y 9mo
1y 11moFeb 1997 - Jan 1999
1991 bear market1991
-44.58%Nov 1991
23d1mo 7d
2moNov 1991 - Jan 1992
1999 bear market1999
-28.50%May 1999
2mo 6d2mo 15d
4mo 21dMar 1999 - Aug 1999

Drawdown Indicators


ALKSBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-96.14%

-56.78%

-39.36%

Max Drawdown (1Y)

Largest decline over 1 year

-22.20%

-9.10%

-13.10%

Max Drawdown (3Y)

Largest decline over 3 years

-30.98%

-18.90%

-12.08%

Max Drawdown (5Y)

Largest decline over 5 years

-33.18%

-25.43%

-7.75%

Max Drawdown (10Y)

Largest decline over 10 years

-80.58%

-33.92%

-46.66%

Current Drawdown

Current decline from peak

-50.97%

-3.21%

-47.76%

Average Drawdown

Average peak-to-trough decline

-67.22%

-10.71%

-56.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.54%

2.04%

+7.50%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alkermes plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Alkermes plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ALKS, comparing it with other companies in the Biotechnology industry. Currently, ALKS has a P/E ratio of 52.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ALKS compared to other companies in the Biotechnology industry. ALKS currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALKS relative to other companies in the Biotechnology industry. Currently, ALKS has a P/S ratio of 5.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALKS in comparison with other companies in the Biotechnology industry. Currently, ALKS has a P/B value of 4.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with ALKS

Add Alkermes plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with ALKS